Phase 3 N=48 Assessment of Efficacy of Zoledronic Acid in the Treatment of Bone Marrow Edema Syndrome
Bone Marrow Edema
Primary: Reduction of the Edema Area — 64.53; 23.97 percentage of edema volume — p==0.006
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=63 Comparing Synthetic Bone Alone Versus Synthetic Bone With Bone Marrow in Bone Lesions
Bone Diseases
Primary: Resorption of Graft Material (GR) Compared at 24 Months — 51; 47 percentage of resorption — p=<0.01
N/A N=101 Role of Bone in Knee Osteoarthritis (OA)
Osteoarthritis, Knee
Primary: Number of Participants With Viable Specimens for Genetic Analysis — 14 participants
Phase 4 N=14 Imaging of Osteonecrosis With Ferumoxytol-Enhanced MRI
Osteonecrosis
Primary: Signal to Noise Ratio (SNR) — 33.82; 129.56 dB — p=0.002
N/A N=67 The Development and Pilot Testing of a New MR Imaging Protocol to Quantify Myeloma Disease Burden and Bone Loss
Myeloma · Monoclonal Gammopathy of Undetermined Significance (MGUS) · Smouldering Myeloma
Primary: Primary Outcome 1: Quantifying Tumour Burden [Correlations With Apparent Diffusion Coefficient (ADC) Measurements] — -0.66; NA; -0.28; 0.48 Pearson's correlation…
Phase 2 N=21 Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI
Bone Cancer · Chondrosarcoma · Ewing's Sarcoma
Primary: T2* Relaxation Time of Bone Sarcomas and Osteomyelitis Subjects — 7.3; 7.7 milliseconds
Phase 4 N=90 Bone Marrow Aspirate Compared to Platelet Rich Plasma for Treating Knee Osteoarthritis
Knee Osteoarthritis
Primary: Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Measurements — 32.1; 35.3; 19.5; 19.8 score on a scale
Phase 2 N=57 The Effect of Glitazone Treatment on Bone Marrow and Bone Marrow Cells
Change in Bone Mineral Density · Change in Bone Marrow Fat Content
Primary: Difference in Percent Change in Bone Mineral Density (BMD) From Baseline to 14 Weeks Between the Rosiglitazone Group and the Placebo Group — -1.3; 0.3 Percent change…
Phase 3 N=78 Prevention of Osteoporosis in Bone Marrow Transplantation (BMT) Patients
Hematological Malignancies
Primary: Percentage Change in Bone Mineral Density From Baseline to 6 and 12 Months — 0.06; -2.61; -3.63; -4.85 Percentage change
N/A N=45 Using Ultrasound Elastography to Predict Development of SOS
Sinusoidal Obstruction Syndrome · Complications of Bone Marrow Transplant
Primary: Sensitivity and Specificity of US for VOD/SOS — 80; 93 percentage of participants
Phase 2 N=18 Cell Therapy for Craniofacial Bone Defects
Cleft Palate · Trauma
Primary: Bone Regeneration — 1.5; 3.3 implant sites
Phase 2 N=123 Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)
Sickle Cell Disease
Primary: Percentage of Participants With Overall Survival (OS) at 2 Years After Biologic Assignment — 89; 94 percentage of participants
Phase 1 N=6 Use of Autologous Concentrated Bone Marrow Aspirate in Preventing Wound Complications in Below Knee Amputation (BKA)
Peripheral Artery Disease · Vascular Disease · Critical Limb Ischemia
Primary: Number of Participants With Treatment-related Adverse Events Occurring During the Enrollment Period as Assessed by the Investigator Using the CTCAE 4.0 Scale. — 2; 0…
N/A N=115 ExAblate (MRgFUS) Treatment of Metastatic Bone Tumors for the Palliation of Pain
Bone Metastases · Multiple Myeloma
Primary: Number of Responders — 54; 6 Participants
Phase 3 N=10 Stem Cell Transplant for Bone Marrow Failure Syndromes
Diamond-Blackfan Anemia · Kostmann's Neutropenia · Shwachman-Diamond Syndrome
Primary: Number of Patients Alive (Survival) at 2 Years — 6 Participants
Phase 2 N=30 Evaluating the Safety and Effectiveness of Bone Marrow Transplants in Children With Sickle Cell Disease (BMT CTN 0601)
Sickle Cell Disease
Primary: Percentage of Participants With Event-Free Survival (EFS) — 76; 69 percentage of participants
N/A N=100 Evaluating Effectiveness of Powered Drill Bone Marrow Biopsy
Plasma Cell Myeloma
Primary: Bone Marrow Core Biopsy Length (in mm) and Artifacts Assessed by the Pathologist — 14; 9.5 Millimeters
Phase 4 N=169 Study on Bone Marrow Morphology in Adults Receiving Romiplostim for Treatment of Thrombocytopenia Associated With Immune Thrombocytopenia Purpura (ITP)
Thrombocytopenia · Idiopathic Thrombocytopenic Purpura
Primary: Percentage of Participants With Collagen Fibrosis — 0.0; 0.0; 3.4 percentage of participants
N/A N=14 Intensity Modulated Total Marrow Irradiation (IM-TMI) for Advanced Hematologic Malignancies
Acute Myeloid Leukemia · Lymphoblastic Leukemia · Acute Leukemia
Primary: Number of Participants With Grade 4 TMI Toxicity — 0; 0; 0; 2 Participants
Phase 2 N=32 Investigation of Mesenchymal Stem Cell Therapy for the Treatment of Osteoarthritis of the Knee
Knee Osteoarthritis
Primary: Knee Injury and Osteoarthritis Outcome Score — 16.71; 10.93; 14.00; 10.47 score on a scale
Phase 1 N=25 Safety/Feasibility of Autologous Mononuclear Bone Marrow Cells in Stroke Patients
Ischemic Stroke
Primary: Study Related Serious Adverse Events (SR-SAE) — 0 Events
N/A N=15 Comparing Powered Ported Bone Marrow Aspiration to Manual Standard Bone Marrow Aspiration Procedures
Healthy
Primary: Quality of Aspirate Specimen Yield Total Score -Jamshidi Manual Standard Device — 4.83; 5.75; 1.5; 1.5 units on a scale
Phase 2 N=26 Bone Tissue Engineering Using Autologous Bone Repair Cell (BRC) Therapy for Sinus Floor Bone Augmentation
Tooth Loss
Primary: Bone Mineral Density of Bone Core — .79; .78 mg/mm^3
Phase 2 N=22 Bone Marrow Transplantation in Young Adults With Severe Sickle Cell Disease
Sickle Cell Disease
Primary: Event -Free Survival Rate — 19 Participants
Phase 2 N=55 Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603)
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma · Leukemia, Myeloid, Acute · Burkitt Lymphoma
Primary: Overall Survival at 180 Days From the Time of Transplant — 83.7; 62.0 percentage of participants
Phase 4 N=162 A Longitudinal 2-year Bone Marrow Study of Eltrombopag in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Purpura, Thrombocytopaenic, Idiopathic
Primary: Number of Participants With Bone Marrow (BM) Fibers of MF Grade 0, 1, 2 and 3 on the European Consensus (EC) Scale at Baseline — 150; 9; 0; 0 Participants
Phase 2 N=202 Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow
Myeloproliferative Disorders · Acute Myelogenous Leukemia · Chronic Myelogenous Leukemia
Primary: Number of Participants Who Experienced Transplant Related Mortality — 5; 4 Participants
Phase 2 N=6 Allo-HCT MUD for Non-malignant Red Blood Cell (RBC) Disorders: Sickle Cell, Thal, and DBA: Reduced Intensity Conditioning, Co-tx MSCs
Sickle Cell Disease · Thalassemia · Diamond-Blackfan Anemia
Primary: Count of Participants With Stable Engraftment Post Hematopoietic Cell Transplantation (HCT) — 3 Participants
N/A N=44 A Study Comparing Use of Manual and Power Bone Marrow Aspiration and Biopsy Devices in Children
Bone Marrow Aspiration and Biopsy Specimen Collection
Primary: Percent of Hematopoietic Tissue Present in Bone Marrow Biopsy Specimens Obtained Using the Manual Device and Powered Device — 42.5; 55.8 % Hematopoetic tissue present…
N/A N=2 Combined Bone Marrow and Renal Transplantation for Hematologic Disorders With End Stage Renal Disease
Multiple Myeloma · Amyloidosis
Primary: Number of Participants Without Renal Allograft Rejection at 6 Months Post-transplant — 1 Participants